EIP is delighted to announce a NEW free-to-access webinar on Spotting the Signs of Metachromatic Leukodystrophy (MLD)  

MLD-S2-M4: The Role of Microglia - The Latest Research and the Implications for Patients with MLD


19 May 2022 


The webinar is now organised. Register to access the video.



  Metachromatic Leukodystrophy (MLD) is a rare hereditary disease characterized by the accumulation of fats called sulfatides. This causes the destruction of the protective fatty layer (myelin sheath) surrounding the nerves in both the central nervous system and the peripheral nervous system, ultimately affecting intellectual and motor function. Early-onset clinical manifestations are often overlooked or confused with other conditions causing confusion among non-trained HCPs at first contact, resulting in misdiagnosis, wrong referral routes and delays in the early start of treatment. Delays in starting treatment have significant consequences on the conditions’ development, and the patient’s health and quality of life. This delay in referral and treatment must be overcome.  
  Language: English ● Duration: 30 minutes followed by questions from the audience  
  Presenter: Alessandra Biffi, Director of the Gene Therapy Program, Dana-Farber/Boston Children’s Cancer and Blood Disorders Center, Harvard Medical School, United States  


  This educational activity is designed for an international audience of General Pediatricians, General Practitioners, Pediatric Neurologists and other physicians and healthcare professionals with an interest in Metabolic Diseases and Genetics.  


  ✓ Introduction to Microglia - a specialised population of macrophages-like cells in the CNS   
  ✓ Reviewing microglia’s involvement in promoting or limiting the pathogenesis of diseases   
  ✓ Exploring the potential for the management and treatments of neurometabolic disorders  

Click below to start your free registration